These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 21788755)

  • 1. Serum concentrations of VEGF and TGF-β1 during exclusive enteral nutrition in IBD.
    Wedrychowicz A; Kowalska-Duplaga K; Jedynak-Wasowicz U; Pieczarkowski S; Sladek M; Tomasik P; Fyderek K
    J Pediatr Gastroenterol Nutr; 2011 Aug; 53(2):150-5. PubMed ID: 21788755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of enteral nutrition therapy on serum angiogenic growth factors concentrations in children].
    Wedrychowicz A; Kowalska-Duplaga K; Pieczarkowski S; Tomasik P; Spodaryk M; Fyderek K
    Przegl Lek; 2010; 67(1):31-5. PubMed ID: 20509569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation.
    Kanazawa S; Tsunoda T; Onuma E; Majima T; Kagiyama M; Kikuchi K
    Am J Gastroenterol; 2001 Mar; 96(3):822-8. PubMed ID: 11280558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical parameters of inflammatory bowel disease in children do not correlate with four common polymorphisms of the transforming growth factor β1 gene.
    Liberek A; Jakóbkiewicz-Banecka J; Kloska A; Świderska J; Kmieć Z; Łuczak G; Wierzbicki P; Liberek T; Marek K; Plata-Nazar K; Sikorska-Wiśniewska G; Kamińska B; Węgrzyn G
    Acta Biochim Pol; 2011; 58(4):641-4. PubMed ID: 22140658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta1 and its receptors in patients with ulcerative colitis.
    Stadnicki A; Machnik G; Klimacka-Nawrot E; Wolanska-Karut A; Labuzek K
    Int Immunopharmacol; 2009 Jun; 9(6):761-6. PubMed ID: 19285572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutritional aspects in inflammatory bowel disease.
    Shamir R
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S86-8. PubMed ID: 19300135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach.
    Day AS; Whitten KE; Lemberg DA; Clarkson C; Vitug-Sales M; Jackson R; Bohane TD
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1609-14. PubMed ID: 16928225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients.
    Rezaie A; Khalaj S; Shabihkhani M; Nikfar S; Zamani MJ; Mohammadirad A; Daryani NE; Abdollahi M
    Ann N Y Acad Sci; 2007 Jan; 1095():305-14. PubMed ID: 17404043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells.
    Baumgart DC; Metzke D; Schmitz J; Scheffold A; Sturm A; Wiedenmann B; Dignass AU
    Gut; 2005 Feb; 54(2):228-36. PubMed ID: 15647187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Enteral Nutrition Support Rich in TGF-β in the Treatment of Inflammatory Bowel Disease in Childhood.
    Agin M; Yucel A; Gumus M; Yuksekkaya HA; Tumgor G
    Medicina (Kaunas); 2019 Sep; 55(10):. PubMed ID: 31546703
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
    Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The circulating common gamma chain (CD132) in inflammatory bowel disease.
    Nielsen OH; Kirman I; Johnson K; Giedlin M; Ciardelli T
    Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
    Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
    Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
    Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
    Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
    Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
    Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
    Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
    Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission.
    Buchanan E; Gaunt WW; Cardigan T; Garrick V; McGrogan P; Russell RK
    Aliment Pharmacol Ther; 2009 Sep; 30(5):501-7. PubMed ID: 19549288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.